Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468767 · ClinicalTrials.gov registry record · Phase 3
Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 356
- Enrollment target
- 20
- Study locations
NCT00468767: Completed Phase 3 study of Atrial Fibrillation, sponsored by Advanz Pharma.
NCT00468767 is a Phase 3 study of Atrial Fibrillation that has completed, run by Advanz Pharma. The registered enrollment target is 356 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00468767, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 356 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Conditions Studied
Interventions
- DRUG Vernakalant Injection 20 mg/mL
Study Locations (20)
Alberta
- Heart Health Institute, Rockyview General Hospital - Calgary
- University of Calgary - Calgary
- University of Alberta Hospital - Edmonton
Ontario
- Hamilton Health Sciences, Hamilton General Hospital - Hamilton
- Ottawa Hospitals (Civic & General) - Ottawa
- Sunnybrook Health Sciences Centre, Emergency Medicine Research Program - Toronto
California
- University of California - Los Angeles
- Regional Cardiology Associates - Sacramento
Florida
- Florida Heart Institute - Orlando
- James Haley VA Hospital - Tampa
Virginia
- Medical College of Virginia - Richmond
- McGuire VA Medical Center - Richmond
Quebec
- Institut de Cardiologie de Montreal - Montreal
- Hopital Notre-Dame du CHUM - Montreal
Massachusetts
- Cardiac Arrhythmia Service, Massachusetts General Hospital - Boston
Michigan
- Thoracic and Cardiovascular Institute - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2003-08 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
What the finished NCT00468767 record still lists
NCT00468767 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Vernakalant Injection 20 mg/mL is the first listed.
NCT00468767 names 20 study sites across 12 states, led by Alberta, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT00468767 about?
NCT00468767 is a clinical study titled "Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation". This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
What is the current status of trial NCT00468767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 356 participants. The study started on 2003-08. Estimated completion is 2004-11.
What conditions does trial NCT00468767 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00468767?
The interventions under investigation include: Vernakalant Injection 20 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00468767?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468767 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00468767's enrollment target sits among peer trials
356 76th of 202 higher than 127 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia